Name: Responsive Respiratory E Cylinder - 15 LPM Regulator And Cart Kit,15 LPM,Each,140-0110
Brand: RESPONSIVE RESPIRATORY INC
SKU: 1187866376
Price: 250.39 USD
Availability: InStock

Responsive Respiratory E Cylinder - 15 LPM Regulator And Cart Kit,15 LPM,Each,140-0110 - 1187866376

By RESPONSIVE RESPIRATORY INC

$250.39

(527 Reviews)

Model

1187866376

Store

Health Products For You
Premium Online Retailer Of Health Products, Medical Supplies & HomeCare Medical Equipments. Healthcare & Healthy Living Store. Affordable Healthcare Essentials.

Manufacturer

RESPONSIVE RESPIRATORY INC

Detail

Responsive Respiratory E Cylinder - 15 LPM Regulator And Cart Kit comes with everything you required to take along anywhere you go. This Oxygen Cylinder comes with an empty aluminum cylinder with plastic cylinder wrench and a standard post valve that fits snugly into the cart, which makes it easy to wheel around. The two legs with anti-slip feet ensure that the cart remains securely in the exact position while moving. This cart provides a height-adjustable handle that allows the user to keep it in the position where they need it.Why choose Responsive Respiratory E Oxygen Cylinders?Comfortable height-adjustable cart handleRolling wheeled cart provides ease in mobilityOxygen Regulator balances the flow of oxygen level

Category

Respiratory

Background COPD is an incurable disease and a leading cause of death worldwide. In mice, fibroblast growth factor (FGF)10 is essential for lung morphogenesis, and in humans, polymorphisms in the human FGF10 gene correlate with an increased susceptibility to develop COPD. Methods We analysed FGF10 signalling in human lung sections and isolated cells from healthy donor, smoker and COPD lungs. The development of emphysema and PH was investigated in Fgf10 +/– and Fgfr2b +/– (FGF receptor 2b) mice upon chronic exposure to cigarette smoke. In addition, we overexpressed FGF10 in mice following elastase- or cigarette smoke-induced emphysema and pulmonary hypertension (PH). Results We found impaired FGF10 expression in human lung alveolar walls and in primary interstitial COPD lung fibroblasts. In contrast, FGF10 expression was increased in large pulmonary vessels i...

>Read More

Background The TANDEM multicentre, pragmatic, randomised controlled trial evaluated whether a tailored psychological intervention based on a cognitive behavioural approach for people with COPD and symptoms of anxiety and/or depression improved anxiety or depression compared with usual care (control). Methods People with COPD and moderate to very severe airways obstruction and Hospital Anxiety and Depression Scale subscale scores indicating mild to moderate anxiety (HADS-A) and/or depression (HADS-D) were randomised 1.25:1 (242 intervention and 181 control). Respiratory health professionals delivered the intervention face-to-face over 6–8 weeks. Co-primary outcomes were HADS-A and HADS-D measured 6 months post-randomisation. Secondary outcomes at 6 and 12 months included: HADS-A and HADS-D (12 months), Beck Depression Inventory II, Beck Anxiety Inventory, ...

>Read More

Background Studies suggest a harmful pharmacogenomic interaction exists between short leukocyte telomere length (LTL) and immunosuppressants in idiopathic pulmonary fibrosis (IPF). It remains unknown if a similar interaction exists in non-IPF interstitial lung disease (ILD). Methods A retrospective, multicentre cohort analysis was performed in fibrotic hypersensitivity pneumonitis (fHP), unclassifiable ILD (uILD) and connective tissue disease (CTD)-ILD patients from five centres. LTL was measured by quantitative PCR for discovery and replication cohorts and expressed as age-adjusted percentiles of normal. Inverse probability of treatment weights based on propensity scores were used to assess the association between mycophenolate or azathioprine exposure and age-adjusted LTL on 2-year transplant-free survival using weighted Cox proportional hazards regression incorporating time-dep...

>Read More

Extract In 2017 the European Respiratory Society/American Thoracic Society [1] recommended moving to a provocative dose causing a 20% decrease in forced expiratory volume in 1 s (PD 20 ) rather than concentration (PC 20 ) for methacholine challenge testing. The rationale was that the PD 20 would be independent of the delivery system, as long as the performance of the device was known, whereas the PC 20 would be device dependent [2–4]. It was recognised that previous quantification of methacholine output performed gravimetrically was highly inaccurate, since up to 75% of the weight change was due to evaporation [1]. Hence the gold standard would be the collection of methacholine at a filter at the mouth and quantifying it by a chemical assay. As quantitative assay of methacholine is difficult for most laboratories, the document suggested that a solution such as salbutamol could...

>Read More

Product Details for 1187866376